Your activity: 38 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Patients who should undergo evaluation for endometrial hyperplasia or endometrial cancer

Patients who should undergo evaluation for endometrial hyperplasia or endometrial cancer
Abnormal uterine bleeding
  • Postmenopausal patients – Any uterine bleeding, regardless of volume (including spotting or staining). Pelvic ultrasound to evaluate endometrial thickness is an alternative to endometrial sampling in appropriately selected patients. A thickened endometrium should be further evaluated with endometrial sampling.
  • Age 45 years to menopause – In any patient, bleeding that is frequent (interval between the onset of bleeding episodes is <21 days), heavy, or prolonged (>8 days). In patients who are ovulatory, this includes intermenstrual bleeding.
  • Younger than 45 years – Any abnormal uterine bleeding in patients with BMI ≥30 kg/m2. In patients with BMI <30 kg/m2, abnormal uterine bleeding that is persistent and occurs in the setting of one of the following: chronic ovulatory dysfunction, other exposure to estrogen unopposed by progesterone, failed medical management of the bleeding, or patients at high risk of endometrial cancer (eg, Lynch syndrome, Cowden syndrome).
  • In addition, endometrial neoplasia should be suspected in premenopausal patients who are anovulatory and have prolonged periods of amenorrhea (six or more months).
Cervical cytology results
  • Presence of AGC-endometrial.
  • Presence of AGC-all subcategories other than endometrial – If ≥35 years of age or at risk for endometrial cancer (risk factors or symptoms).
  • Presence of benign-appearing endometrial cells in patients ≥40 years of age who also have abnormal uterine bleeding or risk factors for endometrial cancer.
Other indications
  • Monitoring of patients with endometrial pathology (eg, endometrial hyperplasia).
  • Screening in patients at high risk of endometrial cancer (eg, Lynch syndrome).
These recommendations are based on an average age of menopause of 51 years. Evaluation of patients who undergo menopause earlier should be individualized based on gynecologic history and risk of endometrial neoplasia.
BMI: body mass index; AGC: atypical glandular cells.
Graphic 58600 Version 15.0